Oxidative stress and mitochondrial dysfunction in atherosclerosis: Mitochondria-targeted antioxidants as potential therapy

Current Medicinal Chemistry

Volumn 16, Issue 35, 2009, Pages 4654-4667

  Victor, V M ^a,b,c   Apostolova, N ^c   Herance, R ^d   Hernandez Mijares, A ^b,e   Rocha, M ^a,b,c  

^a Hospital Universitary Doctor Peset Foundation   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Barcelona Biomedical Research Park   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antioxidant; Atherosclerosis; Endothelium; Mitochondria; Nitric oxide; Reactive oxygen species

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IDEBENONE; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; N,N' DIPHENYL 1,4 PHENYLENEDIAMINE; NITRIC OXIDE SYNTHASE; OXIPURINOL; PROBUCOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; TROLOX C; UBIQUINOL; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE OXIDASE;

AEROBIC EXERCISE; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL METABOLISM; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; LIPID OXIDATION; MITOCHONDRIAL MEMBRANE; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANTIOXIDANTS; ATHEROSCLEROSIS; ENDOTHELIUM; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 72449163629     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789878265     Document Type: Review

References (146)

1. Thom, TJ. International mortality from heart disease: rates and trends. Int. J. Epidemiol., 1989, 18, 20-28
2. Dhalla, N.S.; Temsah, R.M.; Netticadan, T. Role of oxidative stress in cardio-vascular diseases. J. Hypertens., 2000, 18, 655-673 (Pubitemid 30406736)
3. Singh, U.; Jialal, I. Oxidative stress and atherosclerosis. Pathophysiology, 2006, 13, 129-142
4. Gutteridge, J.M. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem., 1995, 41, 1819-1828
5. Green, D.; Kroemer, G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol., 1998, 8, 267-271 (Pubitemid 28310224)
6. Li, J.M.; Shah, A.M. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 287, R1014-30.
7. Ballinger, S.W.; Patterson, C.; Knight-Lozano, C.A.; Burow, D.L.; Conklin, C.A.; Hu, Z.; Reuf, J.; Horaist, C.; Lebovitz, R.; Hunter, G.C.; McIntyre, K.; Runge, M.S. Mitochondrial integrity and function in atherogenesis. Circulation, 2002, 106, 544-549
8. Dimmeler, S.; Zeiher, A.M. Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerosic factors. Regul. Pept., 2000, 90, 19-25.
9. Kowaltowski, A.J.; Vercesi, A.E. Mitochondrial damage induced by conditions of oxidative stress. Free Radic. Biol. Med., 1999, 26, 463-471 (Pubitemid 29013479)
10. Victor, V.M.; Rocha, M.; De la Fuente, M. N-acetylcysteine protects mice from lethal endotoxemia by regulating the redox state of immune cells. Free Radic. Res., 2003, 37, 919-929
11. Victor, V.M.; Rocha, M.; De la Fuente, M. Immune cells: free radicals and antioxidants in sepsis. Int. Immunopharmacol., 2004, 4, 327-347 (Pubitemid 38375967)
12. Victor, V.M.; Rocha, M.; Esplugues, J.V.; De la Fuente, M. Role of free radicals in sepsis: antioxidant therapy. Curr. Pharm. Des., 2005, 11, 3141-3158 (Pubitemid 41149930)
13. Kagan, V.E.; Serbinova, E.A.; Stoyanovsky, D.A.; Khwaja, S.; Packer, L. Assay of ubiquinones and ubiquinols as antioxidants. Methods Enzymol., 1994, 234, 343-354
14. Sheu, S.S., Nauduri, D., Anders, M.W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim. Biophys. Acta, 2006, 1762, 256-265 (Pubitemid 43006031)
15. Valkonen, V.P.; Tuomainen, T.P.; Laaksonen, R. DDAH gene and cardiovascular risk. Vasc. Med., 2005, 10, S45-8.
16. Panza, J.A.; Quyyumi, A.A.; Brush, J.E.; Epstein, S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 1990, 323, 22-27 (Pubitemid 20209468)
17. Zeiher, A.M.; Drexler, H.; Saurbier, B.; Just, H. Endotheliummediated coronary blood flow modulation in humans: Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J. Clin. Invest., 1993, 92, 652-662 (Pubitemid 23262382)
18. Suwaidi, J.A.; Hamasaki, S.; Higano, S.T.; Nishimura, R.A.; Holmes, D.R.; Lerman, A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000, 101, 948-954 (Pubitemid 30131694)
19. Schachinger, V.; Britten, M.B.; Zeiher, A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000, 101, 1899-1906
20. Landmesser, U.; Hornig, B.; Drexler, H. Endothelial function: A critical determinant in atherosclerosis? Circulation, 2004, 109, 27-33. (Pubitemid 38724153)
21. Ghiadoni, L.; Virdis, A.; Magagna, A.; Taddei, S.; Salvetti, A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension, 2000, 35, 501-506 (Pubitemid 30054224)
22. Wolfrum, S.; Jensen, K.S.; Liao, J.K. Endothelium-dependent effects of statins. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 729-736
23. Martens, F.M.; Rabelink, T.J.; Roodt, J.; de Koning, E.J.; Visseren, F.L. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur. Heart J., 2006, 27, 1605-1609
24. Higashi, Y.; Oshima, T.; Ozono, R.; Watanabe, M.; Matsuura, H.; Kajiyama, G. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension, 1995, 25, 898-902.
25. Sanada, M.; Higashi, Y.; Nakagawa, K.; Sasaki, S.; Kodama, I.; Tsuda, M.; Nagai N, Ohama K. Relationship between the angiotensin- converting enzym genotype and forearm vasodilator response to estrogen replacement therapy in postmenopausal. J. Am. Coll. Cardiol., 2001, 37, 1529-1535
26. Higashi, Y.; Sasaki, S.; Nakagawa, K.; Fukuda, Y.; Matsuura, H.; Oshima, T.; Chayama, K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens., 2002, 15, 326-332 (Pubitemid 34408972)
27. Takeshita, Y.; Katsuki, Y.; Katsuda, Y.; Kai, H.; Saito, Y.; Arima, K.; Sasaki, K.; Imaizumi, T. Vitamin C reversed malfunction of peripheral blood-derived mononuclear cells in smokers through antioxidant properties. Circ. J., 2008, 72, 654-659 (Pubitemid 351679420)
28. Goto, C.; Higashi, Y.; Kimura, M.; Noma, K.; Hara, K.; Nakagawa, K.; Kawamura, M.; Chayama, K.; Yoshizumi, M.; Nara, I. Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation, 2003, 108, 530-535 (Pubitemid 36961165)
29. Sasaki, S.; Higashi, Y.; Nakagawa, K.; Kimura, M.; Noma, K.; Sasaki, S.; Hara, K.; Matsuura, H.; Goto, C.; Oshima, T.; Chayama, K. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am. J. Hypertens., 2002, 15, 302-309 (Pubitemid 34408968)
30. Mehta, J.L.; Rasouli, N.; Sinha, A.K.; Molavi, B. Oxidative stress in diabetes: a mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int. J. Biochem. Cell Biol., 2006, 38, 794-803. (Pubitemid 43363412)
31. Guest, T.M.; Vlastos, G.; Alameddine, F.M.; Taylor, W.R. Mechano-regulation of monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Antioxid. Redox Signal., 2006, 8, 1461-1471 (Pubitemid 44726323)
32. Victor, V.M.; Rocha, M. Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr. Pharm. Des., 2007, 13, 845-863 (Pubitemid 46585507)
33. Rocha, M.; Victor, V.M. Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone. Med. Sci. Monit., 2007, 13, 132-145
34. Madamanchi, N.R.; Vendrov, A.; Runge, M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 29-38.
35. Vora, D.K.; Fang, Z.T.; Liva, S.M.; Tyner, T.R.; Parhami, F.; Watson, A.D.; Drake, T.A.; Territo, M.C.; Berliner, J.A. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ. Res., 1997, 80, 810-818
36. Andreassi, M.G.; Botto, N. DNA damage as an emerging risk factor in atherosclerosis. Trends Cardiovasc. Med., 2003, 13, 270-275 (Pubitemid 37159391)
37. Binkova, B.; Smerhovsky, Z.; Strejc, P.; Boubelik, O.; Stavkova, Z.;, Chvalatova, I., Sram, R.J. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat. Res., 2002, 501, 115-128
38. Martinet, W.; Knaapen, M.W.; DeMeyer, G.R.; Herman, A.G.; Kockx, M.M. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation, 2002, 106, 927-932
39. Ceaser, E.; Ramachandran, A.; Levonen, A.L.; Darley-Usmar, V.M. Oxidized low-density lipoprotein and 15-deoxy-delta12,14- PGJ2 increase mitochondrial complex I activity in endothelial cells. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, 2298-2308
40. Asmis, R.; Begley, J.G. Oxidized LDL promotes peroxide mediated mitochondrial dysfunction and cell death in human macrophages: a caspase-3-independent patway. Circ. Res., 2003, 92, 20-29
41. Anderson, E.J.; Lustig, M.E.; Boyle, K.E.; Woodlief, T.L.; Kane, D.A.; Lin, C.T.; Price. J.W.; Kang, L.; Rabinovitch, P.S.; Szeto, H.H.; Houmard, J.A.; Cortright, R.N.; Wasserman, D.H.; Neufer, P.D. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J. Clin. Invest., 2009, 119, 573-581
42. Sreekumar, R.; Unnikrishnan, J.; Fu, A.; Nygren, K.; Short, K.R.; Schimke, J.; Barazzoni, R.; Nair, K.S. Impact of high-fat diet and antioxidant supplement on mitochondrial functions and gene transcripts in rat muscle. Am. J. Physiol. Endocrinol. Metab., 2002, 282, 1055-1061
43. Rapava, E.A.; Akhvlediani, M.V.; Emukhvari, M.G. Modern view on biochemistry of atherosclerosis. Georgian Med. News, 2006, 133, 124-128
44. Camejo, G.; Hurt, E.; Wiklund, O.; Rosengren, B.; Lopez, F.; Bondjers, G. Modifications of low-density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate. Biochim. Biophys. Acta, 1991, 1096, 253-261
45. Brennan, M.L.; Anderson, M.M.; Shih, D.M.; Qu, X.D.; Wang, X.; Mehta, A.C.; Lim LL, Shi W, Hazen SL, Jacob JS, Crowley JR, Heinecke JW, Lusis AJ. Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest., 2001 107, 419-430
46. Hathaway, C.A.; Heistad, D.D.; Piegors, D.J.; Miller, F.J. Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ. Res., 2002, 90, 277-283
47. Kirk, E.A.; Dinauer, M.C.; Rosen, H.; Chait, A.; Heinecke, J.W.; LeBoeuf, R.C. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1529-1535
48. Hsich, E.; Segal, B.H.; Pagano, P.J.; Rey, F.E.; Paigen, B.; Deleonardis, J.; Hoyt, R.F.; Holland, S.M.; Finkel, T. Vascular effects following homozygous disruption of p47(phox) : An essential component of NADPH oxidase. Circulation, 2000, 101, 1234-1236 (Pubitemid 30158608)
49. Kalinina, N.; Agrotis, A.; Tararak, E.; Antropova, Y.; Kanellakis, P.; Ilyinskaya, O.; Quinn, M.T.; Smirnov, V.; Bobik, A. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 2037-2043
50. Guzik, T.J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K.M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 2002, 105, 1656-1662
51. Ohara, Y.; Peterson, T.E.; Harrison, D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest., 1993, 91, 2546-2551 (Pubitemid 23182507)
52. Laursen, J.B.; Somers, M.; Kurz, S.; McCann, L.; Warnholtz, A.; Freeman, B.A.; Tarpey, M.; Fukay, T.; Harrison, D.G. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation, 2001, 103, 1282-1288
53. Victor, V.M.; Nuñez, C.; D'Ocon, P.; Taylor, C.T.; Esplugues, J.V.; Moncada, S. Regulation of oxygen distribution in tissues by endothelial nitric oxide. Circ. Res., 2009, 104, 1178-1183.
54. Bedwell, S.; Dean, R.T.; Jessup, W. The action of defined oxygencentered free radicals on human low-density lipoproteins. Biochem. J., 1989, 262, 707-712 (Pubitemid 19225140)
55. Steinbrecher, U.P. Role of superoxide in endothelial-cell modification of low-density lipoproteins. Biochim. Biophys. Acta, 1988, 959, 20-30.
56. Leeuwenburgh, C.; Hardy, M.M.; Hazen, S.L.; Wagner, P.; Ohishi, S.; Steinbrecher, U.P.; Heinecke, J.W. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem., 1997, 272, 1433-1436
57. Buttery, L.D.; Springall, D.R.; Chester, A.H.; Evans, T.J.; Standfield, E.N.; Parums, D.V.; Yacoub, M.H.; Polak, J.M. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab. Invest., 1996, 75, 77-85. (Pubitemid 26250275)
58. Luoma, J.S.; Stralin, P.; Marklund, S.L.; Hiltunen, T.P.; Sarkioja, T.; Yla-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 157-167 (Pubitemid 28277591)
59. Kettle, A.J.; van Dalen, C.J.; Winterbourn, C.C. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Redox Report, 1997, 3, 257-258
60. Podrez, E.A.; Schmitt, D.; Hoff, H.F.; Hazen, S.L. Myeloperoxidase- generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest., 1999, 103, 1547-1560
61. Stocker, R.; Keaney, J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev., 2004, 84,1381-1478
62. Hazell, L.J.; Arnold, L.; Flowers, D.; Waeg, G.; Malle, E.; Stocker, R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest., 1996, 97, 1535-1544 (Pubitemid 26097044)
63. Carr, A.C.; McCall, M.R.; Frei, B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 1716-1723 (Pubitemid 30470585)
64. Hazell, L.J.; Stocker, R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a highuptake form for macrophages. Biochem. J., 1993, 290, 165-172 (Pubitemid 23081215)
65. Liao, L.; Aw, T.Y.; Kvietys, P.R.; Granger, D.N. Oxidized LDL-induced microvascular dysfunction. Dependence on oxidation procedure. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 2305-2311
66. Kopprasch, S.; Leonhardt, W.; Pietzsch, J.; Kuhne, H. Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells. Atherosclerosis, 1998, 136, 315-324 (Pubitemid 28133421)
67. Savenkova, M.L.; Mueller, D.M.; Heinecke, J.W. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J. Biol. Chem., 1994, 269, 20394-20400
68. Heller, J.I.; Crowley, J.R.; Hazen, S.L.; Salvay, D.M.; Wagner, P.; Pennathur, S.; Heinecke, J.W. p-Hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima. J. Biol. Chem., 2000, 275, 9957-9962
69. Hazell, L.J.; van den Berg, J.J.; Stocker, R. Oxidation of lowdensity lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem. J., 1994, 302, 297-304. (Pubitemid 24256368)
70. Fu, S.; Davies, M.J.; Stocker, R.; Dean, R.T. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque. Biochem J, 1998, 333, 519-525
71. Pennathur, S.; Wagner, J.D.; Leeuwenburgh, C.; Litwak, K.N.; Heinecke, J.W. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J. Clin. Invest., 2001, 107, 853-860
72. White, M.Y.; Edwards, A.V.; Cordwell, J.J.; Van Eyk, J.E. Mitochondria: a mirror into cellular dysfunction in heart disease. Proteomics Clin. Appl., 2008, 2, 845-861
73. Sharma, L.K.; Lu, J.; Bai, Y. Mitochondrial respiratory complex I: structure, function and implication in human diseases. Curr. Med. Chem., 2009, 16, 1266-1277
74. Schlattner, U.; Tokarska-Schlattner, M.; Wallimann, T. Mitochondrial creatine kinase in human health and disease. Biochim. Biophys. Acta, 2006, 1762, 164-180 (Pubitemid 43006023)
75. Collins, T.J.; Berridge, M.J.; Lipp, P.; Bootman, MD. Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J, 2002, 21, 1616-1627
76. DiMauro, S.; Schon, E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med., 2003, 348, 2656-2668
77. Houstek, J.; Pickova, A.; Vojtiskova, A.; Mracek, T.; Pecina, P.; Jesina, P. Mitochondrial diseases and genetic defects of ATP synthase. Biochim. Biophys. Acta, 2006, 1757, 1400-1405 (Pubitemid 44442111)
78. Brookes, P.S.; Yoon, Y.; Robotham, J.L.; Anders, M.W.; Sheu, S.S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol., 2004, 287, 817-833
79. Stavrovskaya, I.G.;, Kristal, B.S. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death?. Free Radic. Biol. Med., 2005, 38, 687-697
80. Di Lisa, F.; Bernardi, P. Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. Cardiovasc. Res., 2005, 66, 222-232 (Pubitemid 40471037)
81. Yakes, F.M.; Van Houten, B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. USA, 1997, 94, 514-519 (Pubitemid 27053665)
82. Ramachandran, A.; Moellering, D.R.; Ceaser, E.; Shiva, S.; Xu, J.; Darley-Usmar, V. Inhibition of mitochondrial protein synthesis results in increased endothelial cell susceptibility to nitric oxide-induced apoptosis. Proc. Natl. Acad. Sci. USA, 2002, 99, 6643-6648 (Pubitemid 34526186)
83. Knight-Lozano, C.A.; Young, C.G.; Burow, D.L.; Hu, Z.Y.; Uyeminami, D.; Pinkerton, K.E.; Ischiropoulos, H.; Ballinger, SW. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation, 2002, 105, 849-854
84. Devary, Y.; Rosette, C.; DiDonato, J.A.; Karin, M. NF-kappa B activation by ultraviolet light not dependent on a nuclear signal. Science, 1993, 261, 1442-1445 (Pubitemid 23334264)
85. Schulze-Osthoff, K.; Beyaert, R.; Vandervoorde, V.; Haegeman, G.; Fiers, W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J., 1993, 12, 3095-3104 (Pubitemid 23232740)
86. Murphy, M.P.; Smith, R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev., 2000, 41, 235-250
87. Wallace, D.C. Mitochondrial diseases in man and mouse. Science, 1999, 283, 1482-1488
88. Jauslin, M.L.; Meier, T.; Smith, R.A.; Murphy, M.P. Mitochondriatargeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J., 2003, 17, 1972-1974
89. Melov, S.; Coskun, P.; Patel, M.; Tuinstra, R.; Cottrell, B.; Jun, A.S.; Zastawny, T.H.; Dizdaroglu, M.; Goodman, S.I.; Huang, T.T.; Miziorko, H.; Epstein, C.J.; Wallace, D.C. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc. Natl. Acad. Sci. USA, 1999, 96, 846-851
90. Melov, S.; Doctrow, S.R.; Schneider, J.A.; Haberson, J.; Patel, M.; Coskun, P.E.; Huffman, K.; Wallace, D.C.; Malfroy, B. Lifespan extension and rescue of spongiform encephalopaty in superoxide dismutase 2 nullizygous mice treated with superoxide dismutasecatalase mimetics. J. Neurosci., 2001, 21, 8348-8353 (Pubitemid 33051432)
91. Schulz, E.; Anter, E.; Keaney, J.F. Oxidative stress, antioxidants, and endothelial function. Curr. Med. Chem., 2004, 11, 1093-1104 (Pubitemid 38585055)
92. Mashima, R.; Witting, P.K.; Stocker, R. Oxidants and antioxidants in atherosclerosis. Curr. Opin. Lipidol., 2001, 12, 411-418
93. Marshall, F.N. Pharmacology and toxicology of probucol. Artery, 1982, 10, 7-21.
94. Tawara, K.; Ishihara, M.; Ogawa, H.; Tomikawa, M. Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit. Jpn. J. Pharmacol., 1986, 41, 211-222 (Pubitemid 16078708)
95. Kita, T.; Nagano, Y.; Yokode, M.; Ishii, K.; Kume, N.; Ooshima, A.; Yoshida, H.; Kawai, C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA, 1987, 84, 5928-5931
96. Carew, T.E.; Schwenke, D.C.; Steinberg, D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA, 1987, 84, 7725-7729 (Pubitemid 18035729)
97. Walldius, G.; Erikson, U.; Olsson, A.G.; Bergstrand, L.; Hadell, K.; Johansson, J.; Kaijser, L.; Lassvik, C.; Mölgaard, J.; Nilsson, S. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol., 1994, 74, 875-883
98. Sawayama, Y.; Shimizu, C.; Maeda, N.; Tatsukawa, M.; Kinukawa, N.; Koyanagi, S.; Kashiwagi, S.; Hayashi, J. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol., 2002, 39, 610-616 (Pubitemid 34158156)
99. Sparrow, C.P.; Doebber, T.W.; Olszewski, J.; Wu, M.S.; Ventre, J.; Stevens, K.A, Chao, Y.S. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N-diphenylphenylenediamine. J. Clin. Invest., 1992, 89, 1885-1891
100. Tangirala, R.K.; Casanada, F.; Miller, E.; Witztum, J.L.; Steinberg, D.; Palinski, W. Effect of the antioxidant N,N-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1625-1630
101. Upston, J.M.; Niu, X.; Brown, A.J.; Mashima, R.; Wang, H.; Senthilmohan, R.; Kettle, A.J.; Dean, R.T.; Stocker, R. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am. J. Pathol., 2002, 160, 701-710 (Pubitemid 34160348)
102. Esterbauer, H.; Gebicki, J.; Puhl, H.; Jurgens, G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med., 1992, 13, 341-390
103. Ingold, K.U.; Bowry, V.W.; Stocker, R.; Walling, C. Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids. The unrecognized consequences of lipid particle size as exemplified by the oxidation of human low density lipoprotein. Proc. Natl. Acad. Sci. USA, 1993, 90, 45-49 (Pubitemid 23010246)
104. Lynch, S.M.; Morrow, J.D.; Roberts, L.J.; Frei, B. Formation of noncyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low-density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest., 1994, 93, 998-1004. (Pubitemid 24087149)
105. Podrez, E.A.; Poliakov, E.; Shen, Z.; Zhang, R.; Deng, Y.;, Sun. M.; Finton, P.J.; Shan, L.; Febbraio, M.; Hajjar, D.P.; Silverstein, R.L.; Hoff, H.F.; Salomon, R.G.; Hazen, S.L. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem., 2002, 277, 38517-38523
106. Stralin, P.; Marklund, S.L. Effects of oxidative stress on expression of extracellular superoxide dismutase, CuZn-superoxide dismutase and Mn-superoxide dismutase in human dermal fibroblasts. Biochem. J., 1994, 298, 347-352
107. Stocker, R. Antioxidant defenses in the vascular wall. In: Oxidative Stress and Vascular Disease, edited by Keaney JF Jr. Boston: Kluwer Academic, 1999, pp. 27-47.
108. T'Hoen, P.A.; Van der Lans, C.A.; Van Eck, M.; Bijsterbosch, M.K.; Van Berkel, T.J.; Twisk, J. Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ. Res., 2003, 93, 262-269 (Pubitemid 36993238)
109. Jung, O.; Marklund, S.L.; Geiger, H.; Pedrazzini, T.; Busse, R.; Brandes, R.P. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ. Res., 2003, 93, 622-629
110. Lapenna, D.; de Gioia, S.; Ciofani, G.; Mezzetti, A.; Ucchino, S.; Calafiore, A.M, Napolitano, A.M.; Di Ilio, C.; Cuccurullo, F.. Glutathione- related antioxidant defenses in human atherosclerotic plaques. Circulation, 1998, 97, 1930-1934 (Pubitemid 28222187)
111. Godin, D.V.; Garnett, M.E.; Cheng, K.M.; Nichols, C.R. Sexrelated alterations in antioxidant status and susceptibility to atherosclerosis in Japanese quail. Can. J. Cardiol., 1995, 11, 945-951
112. Vile, G.F.; Basu-Modak, S.; Waltner, C.; Tyrrell, R.M. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc. Natl. Acad. Sci. USA, 1994, 91, 2607-2610
113. Ishikawa, K.; Sugawara, D.; Wang, X.; Suzuki, K.; Itabe, H.; Maruyama, Y.; Lusis, A.J. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ. Res., 2001, 88, 506-512
114. Yet, S.F.; Layne, M.D.; Liu, X.; Chen, Y.H.; Ith, B.; Sibinga, N.E.; Perrella, M.A. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J., 2003, 17, 1759-1761
115. Togane, Y.; Morita, T.; Suematsu, M.; Ishimura, Y.; Yamazaki, J.I.; Katayama, S. Protective roles of endogenous carbon monoxide in neointimal development elicited by arterial injury. Am. J. Physiol. Heart Circ. Physiol., 2000, 278, 623-632
116. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med., 1994, 330, 1029-1035
117. Liu, X.M.; Chapman, G.B.; Wang, H.; Durante, W. Adenovirus mediated heme oxygenase-1 gene expression stimulates apoptosis in vascular smooth muscle cells. Circulation, 2002, 105, 79-84. (Pubitemid 34049146)
118. Soares, M.P.; Lin, Y.; Anrather, J.; Csizmadia, E.; Takigami, K.; Sato, K.; Grey ST, Colvin RB, Choi AM, Poss KD, Bach FH. Expression of heme-oxygenase-1 can determine cardiac xenograft survival. Nat. Med., 1998, 4, 1073-1077
119. Suarna, C.; Dean, R.T.; May, J.; Stocker, R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1616-1624
120. Willis, G.C.; Fishman, S. Ascorbic acid content of human arterial tissue. Can. Med. Assoc. J., 1955, 72, 500-503
121. Skinner, K.A.; White, C.R.; Patel, R.; Tan, S.; Barnes, S.; Kirk, M.; Darley-Usmar V, Parks DA. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J. Biol. Chem., 1998, 273, 24491-24497 (Pubitemid 28454943)
122. Rao, G.N.; Corson, M.A.; Berk, B.C. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J. Biol. Chem., 1991, 266, 8604-8608
123. Shi, Y.; Evans, J.E.;, Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 2003, 425, 516-521
124. Dabbagh, A.J.; Frei, B. Human suction blister interstitial fluid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems. J. Clin. Invest., 1995, 96, 1958-1966
125. Smith, E.B. The relationship between plasma and tissue lipids in human atherosclerosis. Adv. Lipid Res., 1974, 12, 1-49.
126. Keaney, J.F.; Simon, D.I.; Freedman, J.E. Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB J., 1999, 13, 965-975
127. Boscoboinik, D.; Szewczyk, A.; Hensey, C.; Azzi, A. Inhibition of cell proliferation by α-tocopherol. Role of protein kinase C. J. Biol. Chem., 1991, 266, 6188-6194 (Pubitemid 21906202)
128. Letters, J.M.; Witting, P.K.; Christison, J.K.; Westin Eriksson, A.W.; Pettersson, K.; Stocker, R. Time-dependent changes to lipids and antioxidants in plasma and aortae of apoE-knockout mice. J. Lipid Res., 1999, 40, 1104-1112 (Pubitemid 29287881)
129. Thomas, S.R.; Leichtweis, S.B.; Pettersson, K.; Croft, K.D.; Mori, T.A.; Brown, A.J.; Stocker, R. Dietary co-supplementation with vitamin E and coenzyme Q10 inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 585-593 (Pubitemid 32323393)
130. Mohr, D.; Bowry, V.W.; Stocker, R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low density lipoprotein to the initiation of lipid peroxidation. Biochim. Biophys. Acta, 1992, 1126, 247-254
131. Witting, P.K.; Pettersson, K.; Letters, J.; Stocker, R. Antiatherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice. Free Radic. Biol. Med., 2000, 29, 295-305. (Pubitemid 30734913)
132. Turunen, M.; Wehlin, L.; Sjoberg, M.; Lundahl, J.; Dallner, G.; Brismar, K.; Sindelar, P.J. beta2-Integrin and lipid modifications indicate a non-antioxidant mechanism for the anti-atherogenic effect of dietary coenzyme Q10. Biochem. Biophys. Res. Commun., 2002, 296, 255-260
133. Hodqson, J.M.; Watts, G.F.; Playford, D.A.; Burke, V.; Croft, K.D. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur. J. Clin. Nutr., 2002, 56, 1137-1142
134. Watts, G.F.; Playford, D.A.; Croft, K.D.; Ward, N.C.; Mori, T.A.; Burke, V. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia, 2002, 45, 420-426 (Pubitemid 34267365)
135. Asin-Cayuela, J.; Manas, A.R.; James, A.M.; Smith, R.A.; Murphy, MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett., 2004, 571, 9-16.
136. Smith, R.A.; Porteous, C.M.; Coulter, C.M.; Murphy, M.P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem., 1999, 263, 709-716.
137. Brown, S.E.; Ross MF, Sanjuan-Pla A, Manas AR, Smith RA, Murphy MP. Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphonium-conjugated alphalipoyl derivative. Free Radic. Biol. Med., 2007, 42, 1766-1780 (Pubitemid 46759581)
138. Murphy, M.P.; Smith, R.A. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 629-656 (Pubitemid 46272141)
139. Smith, R.A.; Adlam, V.J.; Blaikie, F.H.; Manas, A.R.; Porteous, C.M.; James, A.M.; Ross. M.F.; Logan, A.; Cochemé, H.M.; Trnka, J.; Prime, T.A.; Abakumova, I.; Jones, B.A.; Filipovska, A.; Murphy, M.P. Mitochondria-targeted antioxidants in the treatment of disease. Ann. N. Y. Acad. Sci. 2008, 1147, 105-111
140. Ross, M.F.; Kelso, G.F.; Blaikie, F.H.; James, A.M.; Cochemé, H.M.; Filipovska, A.; Da Ros, T.; Hurd, T.R.; Smith, R.A.; Murphy, M.P. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc.), 2005, 70, 222-230 (Pubitemid 40512331)
141. Koopman, W.J.; Verkaart, S.; Visch, H.J.; van der Westhuizen, F.H.; Murphy, M.P.; van den Heuvel, L.W.; Smeitink, J.A.; Willems, P.H. Inhibition of complex I of the electron transport chain causes O2-mediated mitochondrial outgrowth. Am. J. Physiol. Cell. Physiol., 2005, 288, C1440-50.
142. Smith, R.A.; Porteous, C.M.; Gane, A.M.; Murphy, M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA, 2003, 100, 5407-5412
143. Adlam, V.J.; Harrison, J.C.; Porteous, C.M.; James, A.M.; Smith, R.A.; Murphy, M.P.; Sammut, I.A. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J., 2005, 19, 1088-1095
144. Esplugues, J.V.; Rocha, M.; Nuñez, C.; Bosca, I.; Ibiza, S.; Herance, J.R.; Ortega, A.; Serrador, J.M.; D'Ocon, P.; Victor, V.M. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res., 2006, 99, 1067-1075 (Pubitemid 44729930)
145. Lipinski, C.A.; Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26. (Pubitemid 33653411)
146. White, C.R.; Datta, G.; Zhang, Z.; Gupta, H.; Garber, D.W.; Mishra, V.K.; Palgunachari, M.N.; Handattu, S.P.; Chaddha, M.; Anantharamaiah, G.M. HDL therapy for cardiovascular diseases: the road to HDL mimetics. Curr Atheroscler. Rep. 2008 10, 405-412.